BioSpace News Archive

Cyclacel Pharmaceuticals, Inc. announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,968,945 shares of common stock, series A warrants to purchase up to 4,968,945 shares of common stock and short-term series B warrants to purchase up to 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock and accompanying warrants in a private placement priced at-the-market under Nasdaq rules.

Harmony Biosciences, announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets.

Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., disclosed that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® for Quallent Pharmaceuticals, in alignment with its U.S. commercialization agreement with Teva.

Foresee Pharmaceuticals, announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia.

Scenic Biotech announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.

MannKind Corporation announced that it will proceed with a first-in-human Phase 1 study of nintedanib DPI for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the submission of a New Drug Application to the U.S. Food and Drug Administration for approval of ET-400, Eton’s proprietary patented formulation of hydrocortisone oral solution.

LSL PHARMA GROUP INC. reported its financial results for the year-ended December 31, 2023.

ASLAN Pharmaceuticals announced that it will host a virtual Key Opinion Leader Event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market”, to be held on Tuesday, May 7, 2024 from 8:00 AM ET to 9:00 AM ET.

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 30, 2024.